Full Text View
Tabular View
No Study Results Posted
Related Studies
Angeliq Regulatory Post Marketing Surveillance (Angeliq rPMS)
This study has been completed.
Study NCT01064453   Information provided by Bayer

First Received on February 5, 2010.   Last Updated on January 4, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Postmenopausal Period
Osteoporosis, Postmenopausal
Additional conditions recognized in this trial
Osteoporosis
More general conditions related to this trial
Bone Diseases
Bone Diseases, Metabolic
Musculoskeletal Diseases
Interventions listed in this trial
E2/DRSP (Angeliq, BAY86-4891)
Additional drug interventions recognized in this trial
Drospirenone and ethinyl estradiol combination
More general drug interventions related to this trial
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses
Sponsors listed in this trial
Bayer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services